file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.

txt

Key Speakers

Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics

Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health
Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards,
Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics

Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010

Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological
breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new
generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and
nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic
vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the
period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the
most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct
areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant,
and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement
successful strategies and innovative technologies to develop more effective vaccines. Gain insights
through industry led case studies and discussions with key decision markers from the vaccines sector.
Network and collaborate with global professionals to keep up-to-date with future trends and exploring
business opportunities at the two-day event.

By attending this conference you will gain insights on:

• Overcoming challenges to cancer vaccine development

• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based
drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A
(H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (1 of 7)7/26/2010 2:19:04 PM

 file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.txt

• Good supply chain management practices for vaccine distribution

Who will be there?

Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital

Sponsorship and exhibition opportunities:

This event offers a unique opportunity to meet and do business with some of the key players in the
pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this
event by:

• Hosting a networking drinks reception

• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.

If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine
Innovation and Cell Line Development Conference, please contact us:

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (2 of 7)7/26/2010 2:19:04 PM

 file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.txt

Phone: +91 22 27578668

Email : raju@bharatbook.com

Day 1

Vaccine Research & Innovation 2010

Thursday 2nd September 2010

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan

Dr. David Kirke

Associate Director - Regulatory Affairs
ERA Consulting

10:50 Evaluating the immune response to combination vaccines

• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene
therapy and protein based drugs early

Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology

11:30 Morning refreshments

11:50 High-throughput stable cell line generation

• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian
stable cell lines
• Stabilisation of cell lines

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (3 of 7)7/26/2010 2:19:04 PM

 file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.txt

12.30 Development of avian cell lines dedicated to vaccines manufacturing

• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins

Jean Marc Balloul

New Venture Development Director
Transgene

13:10 Networking lunch

14.10 Biologics cell line and process development

• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell

14:50 Manufacturing and purification strategies of conjugate vaccines

• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies

15:30 Afternoon refreshments

15:50 Safety monitoring in vaccine development and immunisation

• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)

16:30 Challenges to cancer vaccine development

• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials

Dr. Barbara Guinn

Cancer Sciences Division

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (4 of 7)7/26/2010 2:19:04 PM

 file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.txt

University of Southampton

17:10 Closing remarks from the chair

17:20 Networking drinks

Take your discussions further and build new

relationships in a relaxed and informal setting.

Day 2

Vaccine Research & Innovation 2010

Friday 3rd September 2010

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Development of a pneumococcal vaccine comprising highly conserved proteins

• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved
among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates

Alexander von Gabain

Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell

10:50 From trial and error to rational design of adjuvant vaccines

• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova

11:30 Morning refreshments

11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A
(H1N1) vaccines
Dr. Bassam Hallis

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (5 of 7)7/26/2010 2:19:04 PM

 file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.txt

General Project Manager

Centre for Emergency Preparedness and Response
Health Protection Agency

12:30 Vaccine development & early clinical research

(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles

13:10 Networking lunch

14:10 Case study: Developing the next generation of therapeutic vaccines

The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular
pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics

14:50 Surface proteome analysis as a fast-track to vaccine discovery

• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics

15:30 Afternoon refreshments

15:50 Challenges in adult immunisation

• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines

16.30 Accelerating new vaccine introduction in the developing world

• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (6 of 7)7/26/2010 2:19:04 PM

 file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%20Vaccine%20Research%20&%20Innovation%202010.txt

• Good supply chain management practices for vaccine distribution

17:10 Chair’s closing remarks

17:20 End of Conference

For more information visit

http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-
2010.html

OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com

file:///C|/Documents%20and%20Settings/user29/Desktop...0on%20Vaccine%20Research%20&%20Innovation%202010.txt (7 of 7)7/26/2010 2:19:04 PM